CN106728128A - Prevent and treat the pharmaceutical composition of glaucoma - Google Patents

Prevent and treat the pharmaceutical composition of glaucoma Download PDF

Info

Publication number
CN106728128A
CN106728128A CN201611133180.6A CN201611133180A CN106728128A CN 106728128 A CN106728128 A CN 106728128A CN 201611133180 A CN201611133180 A CN 201611133180A CN 106728128 A CN106728128 A CN 106728128A
Authority
CN
China
Prior art keywords
weight
weight portion
ethanol
pharmaceutical composition
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611133180.6A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Haoyu Qingtian Medicine Technology Co ltd
Original Assignee
Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Haoyu Qingtian Medicine Technology Co ltd filed Critical Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority to CN201611133180.6A priority Critical patent/CN106728128A/en
Publication of CN106728128A publication Critical patent/CN106728128A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Pharmaceutical composition of glaucoma and preparation method thereof is prevented and treated the invention discloses a kind of, pharmaceutical composition of the present invention is with Oblongleaf Heterostemma, multiflora rose, Sisalagenin, capillarisin, globe amaranth as bulk drug, proportioning is formed, routinely various formulations can be made by preparation process, prevent and treat glaucoma evident in efficacy.

Description

Prevent and treat the pharmaceutical composition of glaucoma
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition for preventing and treating glaucoma and its preparation side Method.
Background technology
Glaucoma is caused because intraocular pressure is raised regarding nipple infringement and the illness in eye of defect of visual field, and its blind rate is located at eye Section second.The pathologic basis of visual function damage are caused by glaucoma:Retinal ganglial cells (RGC) progressive is dead and refreshing Lost through fiber.In recent years, developing rapidly with molecular biology, it is believed that Apoptosis is that glaucoma causes RGC progressive One of main mechanism of reduction.After Glaucoma Surgery, the intraocular pressure of most of patients can be controlled in normal level, but some patientss Optic nerve lesion can continue development.Therefore, except reduce intraocular pressure in addition to, resist RGC apoptosis and protection optic nerve turn at present and The major subjects of following glaucoma-controlling.
The final purpose of glaucoma treatment is to prevent optic nerve lesion, protects visual function.The side of glaucoma is treated at present Method is mainly reduction intraocular pressure, and to slow down the progress of optic nerve lesion, to pressure dependency glaucoma, its pathological development can be controlled, Even there is the possibility of reverse；But for non-pressure dependence glaucoma, even if medicine and the effective control intraocular pressure of operation, its lesion Still can slowly develop.Therefore, in addition to intraocular pressure is reduced, people increasingly pay close attention to improvement and are protected regarding teat blood flow perfusion and reinforcement optic nerve The treatment of shield.Think in the traditional Chinese medical science, glaucoma is that seven feelings are violated, cause stagnation of liver qi not relax, caused by energy stagnation and blood stasis.Therefore, using work The Chinese medicine of blood stagnation resolvation has protective effect to glaucoma visual function.The treatment of glaucoma protecting visual function is not made a breakthrough yet at present Property progress under, using Chinese medicine protection optic nerve clinical research and screening medicine in terms of have great significance.
Oblongleaf Heterostemma：This product is dicotyledon medicine Asclepiadaceae Winged Heterostemma platymiscium Oblongleaf Heterostemma Hetrostemma The complete stool of oblongifolium Cost..Autumn harvests, and dries.【Nature and flavor】It is slight bitter, sweet；It is flat.【Return through】Liver Channel.【Function master Control】Lactagogue.Qi and blood stasis after main product；Agalactia.【Former phytomorph】Weak winding liana.Complete stool has milk, and stem is by 2 row Pubescence.Leaf opposite；Petiole 2-4cm long；Blade Long Circle, dilute ovate Long Circle, 7.5-11cm long, 3.5-4.5cm wide, tip is sharp Point, basal circular；Per side 5-7 bars, arc rises lateral vein.Umbrella shape shape cyme axillary, 2-3cm long is blossomed 4-5；Calyx 5 Drastic crack, inner face base portion has body of gland about 10；Corolla outside light green, inner face yellow, spoke shape, diameter 1-1.5cm；Corolla splits levies 5, Cover to the right；Paracorolla five-pointed star aristiform, the every room 1 of massula, square circular, uprightly.Follicle radish fruit wire lanceolar, is up to 12cm, diameter about 1cm, it is tapering to tip.Seed is up to 2cm, about 3mm wide, white thin,tough silk matter kind hair of the seed tool up to 3cm.Flower Month phase 8-10, the fruiting period 9-12 months.Record in dictionary of medicinal plant.
Multiflora rose：It is the sisters Rosa multiflora Thunb.var.carnea Thory of rose family gul seven The root and leaf of [P.multiflora Thunb.var.platyphylla Thory].Root, whole year can be adopted, and clean, and section is dried； Leaf, summer, autumn harvesting, dries standby.【Nature and flavor】Hardship is flat；Micro-puckery.【Return through】Liver；Gallbladder channel.【Indication】Clearing away heat and eliminating dampeness, it is soothing the liver Cholagogic.Main jaundice；Mass in the abdomen；Women leukorrhea.【Chemical analysis】Root skin contains tannin（23%）, flower (astragalin) containing astragalin And volatile oil etc..【Former phytomorph】Seven sisters machakas, about 2m high.The many spines of stem, branch.Odd number winglike compound leaf；Leaflet Usual 9 pieces, oval, tip is blunt or point, base portion blunt round, edge tool tooth, and two sides is without hair；Stipule is extremely obvious.Most fasciations are spent, It is conical corymb；Pollen color, fragrance；There are a small number of glandular hairs on bennet；Sepal 5, petal 5, polyphyll；Stamen is most；Style Without hair.Achene, it is raw inside ring-type or gyalectiform holder.The month at florescence 5-6, the fruiting period 8-9 months.Record in dictionary of medicinal plant.
Globe amaranth：This product is the dry capitulum of Gorgon euryale section plant globe amaranth Gomphrena globosa L..Autumn is spent Harvested when in full bloom, dried.【Nature and flavor】It is sweet, put down.【Function with cure mainly】Eliminating the phlegm, relievings asthma.For chronic bronchitis, asthmatic branch gas Guan Yan.【Proterties】This product is spherical in shape or square is circular, 1.5~2cm of diameter, rose, pink or white.Phyllary 2 is green Color, heart-shaped or avette, two masks hair, following surface is close.Flower imbricate arrangement, often spends 1 avette dry film matter shape bract of tool；Small bud Piece 2, triangular shape lanceolar, rose or white, film quality have gloss；Perianth 5, wire lanceolar, color is shallow, close long by white Pubescence；Stamen 5, filigree joint, flower pesticide micro stretching goes out；Gynoecium 1.Utricle is spherical, inside there is brown seed 1.Body is light.Gas is micro-, lightly seasoned. Record in Shanghai City Chinese medicine standard 1994 (Shanghai Health Bureau).
Sisalagenin（Tigogenin）：CAS 77-60-1, molecular formula C27H44O3, molecular weight 416.64.【Biology is living Property】The raw material of synthetic hormone.【Ingredient origin】Sisal hemp Agave sisalana.
Capillarisin（Capillarisin）：CAS 56365-38-9, molecular formula C16H12O7, molecular weight 316.26. 【Pharmacological action】Cholagogic.【Ingredient origin】Feverfew Artemisia capillaris aerial part.
2 bulk drug chemical constitutions：
Capillarisin（Capillarisin）Sisalagenin（Tigogenin）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided it is a kind of effectively prevent and treat glaucoma pharmaceutical composition and Its preparation method.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for being made the bulk drug of the pharmaceutical composition for preventing and treating glaucoma be：
Oblongleaf Heterostemma 520-530 weight portion multiflora rose's 512-520 weight portion Sisalagenin 24-28 weight portion capillarisins 20-26 weight portion globe amaranth 540-550 weight portions.
The pharmaceutical composition for preventing and treating glaucoma is preferably used in, is made up of the bulk drug of following weight portion：
The weight portion thousand of 26 weight portion capillarisin of Oblongleaf Heterostemma 525 weight portion multiflora rose, 517 weight portion Sisalagenin 23 Day red 545 weight portion.
A kind of pharmaceutical composition for preventing and treating glaucoma, it is characterised in that pharmaceutical composition can be using the routine side of galenic pharmacy Method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition for preventing and treating glaucoma, it is characterised in that pharmaceutical composition is anti-with what chemical drugs or Chinese medicine were constituted Control glaucoma medicine.
A kind of preparation method of the pharmaceutical composition for preventing and treating glaucoma, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Oblongleaf Heterostemma 520-530 weight portion multiflora rose's 512-520 weight portion Sisalagenins 24-28 weight portion capillarisin 20-26 weight portion globe amaranth 540-550 weight portions；
Preparation method：
（1）Oblongleaf Heterostemma, multiflora rose, Sisalagenin, capillarisin, globe amaranth are taken by bulk drug proportioning, is mixed, with weight hundred Divide the ethanol of specific concentration 39% as solvent, 31.5 DEG C of temperature extractions take, and extraction time is 13 times, and each extraction time is 14 hours, often Secondary solvent load is 63 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into phase To density 1.13, filtration, liquid is first washed with water by HP30 large pore resin absorption columns, then with the second of weight percent concentration 15% Alcoholic solution elutes HP30 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 15%, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 24 times is carried every time The time is taken for 0.4 hour, each solvent load is 17 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.06 is concentrated into, filtered, liquid is first washed with water, then use weight by DM18 large pore resin absorption columns The ethanol solution of percent concentration 68% elutes DM18 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 68%, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Preferred a kind of preparation method of the pharmaceutical composition for preventing and treating glaucoma, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：The weight portion of 525 weight portion multiflora rose of Oblongleaf Heterostemma, 517 weight portion Sisalagenin 26 The weight portion of 23 weight portion globe amaranth of capillarisin 545；
Preparation method：
（1）Oblongleaf Heterostemma, multiflora rose, Sisalagenin, capillarisin, globe amaranth are taken by bulk drug proportioning, is mixed, with weight hundred Divide the ethanol of specific concentration 39% as solvent, 31.5 DEG C of temperature extractions take, and extraction time is 13 times, and each extraction time is 14 hours, often Secondary solvent load is 63 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into phase To density 1.13, filtration, liquid is first washed with water by HP30 large pore resin absorption columns, then with the second of weight percent concentration 15% Alcoholic solution elutes HP30 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 15%, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 24 times is carried every time The time is taken for 0.4 hour, each solvent load is 17 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.06 is concentrated into, filtered, liquid is first washed with water, then use weight by DM18 large pore resin absorption columns The ethanol solution of percent concentration 68% elutes DM18 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 68%, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for preventing and treating glaucoma, it is characterised in that pharmaceutical composition can use preparation Conventional method prepares piece agent or capsule or dripping pill.
A kind of preparation method of the pharmaceutical composition for preventing and treating glaucoma, it is characterised in that pharmaceutical composition and chemical drugs or in Medicine composition preventing and treating glaucoma medicine.
It is evident in efficacy that pharmaceutical composition prevents and treats glaucoma.
Specific embodiment
Embodiment 1：Prevent and treat pharmaceutical composition of glaucoma and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of glaucoma be：Oblongleaf Heterostemma 525g multiflora rose 517g sisal hemps Sapogenin 26g capillarisin 23g globe amaranths 545g；
Preparation method：
（1）Oblongleaf Heterostemma, multiflora rose, Sisalagenin, capillarisin, globe amaranth are taken by bulk drug proportioning, is mixed, with weight hundred Divide the ethanol of specific concentration 39% as solvent, 31.5 DEG C of temperature extractions take, and extraction time is 13 times, and each extraction time is 14 hours, often Secondary solvent load is 63 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into phase To density 1.13, filtration, liquid is first washed with water by HP30 large pore resin absorption columns, then with the second of weight percent concentration 15% Alcoholic solution elutes HP30 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 15%, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 24 times is carried every time The time is taken for 0.4 hour, each solvent load is 17 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.06 is concentrated into, filtered, liquid is first washed with water, then use weight by DM18 large pore resin absorption columns The ethanol solution of percent concentration 68% elutes DM18 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 68%, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Prevent and treat pharmaceutical composition of glaucoma and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of glaucoma be：Oblongleaf Heterostemma 520g multiflora rose 520g sisal hemps Sapogenin 24g capillarisin 26g globe amaranths 540g；
Preparation method：
（1）Oblongleaf Heterostemma, multiflora rose, Sisalagenin, capillarisin, globe amaranth are taken by bulk drug proportioning, is mixed, with weight hundred Divide the ethanol of specific concentration 39% as solvent, 31.5 DEG C of temperature extractions take, and extraction time is 13 times, and each extraction time is 14 hours, often Secondary solvent load is 63 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into phase To density 1.13, filtration, liquid is first washed with water by HP30 large pore resin absorption columns, then with the second of weight percent concentration 15% Alcoholic solution elutes HP30 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 15%, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 24 times is carried every time The time is taken for 0.4 hour, each solvent load is 17 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.06 is concentrated into, filtered, liquid is first washed with water, then use weight by DM18 large pore resin absorption columns The ethanol solution of percent concentration 68% elutes DM18 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 68%, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Prevent and treat pharmaceutical composition of glaucoma and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of glaucoma be：Oblongleaf Heterostemma 530g multiflora rose 512g sisal hemps Sapogenin 28g capillarisin 20g globe amaranths 550g；
Preparation method：
（1）Oblongleaf Heterostemma, multiflora rose, Sisalagenin, capillarisin, globe amaranth are taken by bulk drug proportioning, is mixed, with weight hundred Divide the ethanol of specific concentration 39% as solvent, 31.5 DEG C of temperature extractions take, and extraction time is 13 times, and each extraction time is 14 hours, often Secondary solvent load is 63 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into phase To density 1.13, filtration, liquid is first washed with water by HP30 large pore resin absorption columns, then with the second of weight percent concentration 15% Alcoholic solution elutes HP30 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 15%, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 24 times is carried every time The time is taken for 0.4 hour, each solvent load is 17 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.06 is concentrated into, filtered, liquid is first washed with water, then use weight by DM18 large pore resin absorption columns The ethanol solution of percent concentration 68% elutes DM18 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 68%, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 630g of Example 1, adds starch 720g, mixes, and granulation is dried, plus microcrystalline cellulose 180g, stearic Sour magnesium 10g, mixes, and is pressed into 5000, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 340g of Example 2, adds starch 470g, mixes, and granulation is dried, whole grain, adds appropriate stearic acid Magnesium, mixes, and encapsulated 1800, obtains final product medicament composition capsule.
Embodiment 6：The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 209g water-baths and boil molten, add the pharmaceutical composition 13g of embodiment 3, fully stir Mix uniform, with atoleine as cooling agent, put glass tube（4*80cm）In, chilling temperature is 5 DEG C, and drip internal-and external diameter is 7.0/ 2.0 (mm/mm), drip is 2.5cm away from liquid level, and drop speed is optimum condition with every point 54 drop, and the cold of dripping pill surface is blotted with cotton Solidifying agent, obtains final product medicament composition dropping pills.
Embodiment 7：Prevent and treat the pharmaceutical composition of glaucoma
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of glaucoma be：
The weight portion of 580 weight portion capillarisin of multiflora rose, 25 weight portion globe amaranth 360.
Embodiment 8：Prevent and treat the pharmaceutical composition of glaucoma
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of glaucoma be：
The weight portion of 40 weight portion capillarisin of Sisalagenin, 12 weight portion globe amaranth 350.
Embodiment 9：Prevent and treat the pharmaceutical composition of glaucoma
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of glaucoma be：
The weight portion of 70 weight portion capillarisin of Sisalagenin, 50 weight portion globe amaranth 650.
Experimental example 1：Prevent and treat the experimental study of glaucoma
1 data and method
Case and packet:This group 40 (50 eyes) is city's Patients during Hospital Ward, wherein 35 is acute angle-closure green light Eye stage of attack, 5 is chronic angle closure glaucoma's progressive stage.Row trabeculectomy, intraocular pressure≤21mmHg.40 Li Zhong treatment groups 20 (25 eyes) combination of oral medication（The pharmaceutical composition of embodiment 1）Each 1.5g, 3 times a day, takes medicine continuously 30 days.Control group 20 (25 eyes) unused drug therapies.Had an eyesight test and the visual field simultaneously with control group before and after treatment group's medication, protected by an ophthalmology Scholar is special to be responsible for checking and recording.
Criterion of therapeutical effect:Eyesight (standard logarithmic visual acuity chart):Eyesight increases by >=2 behaviors and improves；Visual impairment<2 behaviors regress. The visual field (perimeter of Suzhou Medical Instruments Factory's production):The visual field expands >=5 ° to improve；Expand<5 ° is constant.
2 results
Two groups of results are relatively shown in Table 1.
Table 1 is taken medicine the comparing of front and rear treatment group's eyesight, the visual field and control group
Eyesight is poor significant difference, and relatively there are significant difference, P in the visual field<0.05.

Claims (8)

1. a kind of pharmaceutical composition for preventing and treating glaucoma, it is characterised in that be made the composition and weight of the bulk drug of the pharmaceutical composition Measuring part is：
Oblongleaf Heterostemma 520-530 weight portion multiflora rose's 512-520 weight portion Sisalagenin 24-28 weight portion capillarisins 20-26 weight portion globe amaranth 540-550 weight portions.
2. a kind of pharmaceutical composition for preventing and treating glaucoma according to claim 1, it is characterised in that be made the pharmaceutical composition Bulk drug composition and weight portion be：
The weight portion thousand of 26 weight portion capillarisin of Oblongleaf Heterostemma 525 weight portion multiflora rose, 517 weight portion Sisalagenin 23 Day red 545 weight portion.
3. a kind of pharmaceutical composition for preventing and treating glaucoma according to claim 1, it is characterised in that pharmaceutical composition can be adopted Piece agent or capsule or dripping pill are prepared with the conventional method of galenic pharmacy.
4. a kind of pharmaceutical composition for preventing and treating glaucoma according to claim 1, it is characterised in that pharmaceutical composition and chemistry The preventing and treating glaucoma medicine of medicine or Chinese medicine composition.
5. a kind of preparation method of the pharmaceutical composition for preventing and treating glaucoma, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Oblongleaf Heterostemma 520-530 weight portion multiflora rose's 512-520 weight portion Sisalagenins 24-28 weight portion capillarisin 20-26 weight portion globe amaranth 540-550 weight portions；
Preparation method：
（1）Oblongleaf Heterostemma, multiflora rose, Sisalagenin, capillarisin, globe amaranth are taken by bulk drug proportioning, is mixed, with weight hundred Divide the ethanol of specific concentration 39% as solvent, 31.5 DEG C of temperature extractions take, and extraction time is 13 times, and each extraction time is 14 hours, often Secondary solvent load is 63 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into phase To density 1.13, filtration, liquid is first washed with water by HP30 large pore resin absorption columns, then with the second of weight percent concentration 15% Alcoholic solution elutes HP30 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 15%, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 24 times is carried every time The time is taken for 0.4 hour, each solvent load is 17 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.06 is concentrated into, filtered, liquid is first washed with water, then use weight by DM18 large pore resin absorption columns The ethanol solution of percent concentration 68% elutes DM18 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 68%, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. a kind of preparation method of the pharmaceutical composition for preventing and treating glaucoma according to claim 5, it is characterised in that by as follows It is prepared by step：
The composition and weight portion of bulk drug be：The weight portion of 525 weight portion multiflora rose of Oblongleaf Heterostemma, 517 weight portion Sisalagenin 26 The weight portion of 23 weight portion globe amaranth of capillarisin 545；
Preparation method：
（1）Oblongleaf Heterostemma, multiflora rose, Sisalagenin, capillarisin, globe amaranth are taken by bulk drug proportioning, is mixed, with weight hundred Divide the ethanol of specific concentration 39% as solvent, 31.5 DEG C of temperature extractions take, and extraction time is 13 times, and each extraction time is 14 hours, often Secondary solvent load is 63 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into phase To density 1.13, filtration, liquid is first washed with water by HP30 large pore resin absorption columns, then with the second of weight percent concentration 15% Alcoholic solution elutes HP30 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 15%, reclaims ethanol, and concentration is dry It is dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 24 times is carried every time The time is taken for 0.4 hour, each solvent load is 17 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.06 is concentrated into, filtered, liquid is first washed with water, then use weight by DM18 large pore resin absorption columns The ethanol solution of percent concentration 68% elutes DM18 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 68%, Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. a kind of preparation method of the pharmaceutical composition for preventing and treating glaucoma according to claim 5, it is characterised in that medicine group Compound can prepare piece agent or capsule or dripping pill using the conventional method of galenic pharmacy.
8. a kind of preparation method of the pharmaceutical composition for preventing and treating glaucoma according to claim 5, it is characterised in that medicine group Compound and chemical drugs or Chinese medicine composition preventing and treating glaucoma medicine.
CN201611133180.6A 2016-12-10 2016-12-10 Prevent and treat the pharmaceutical composition of glaucoma Withdrawn CN106728128A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611133180.6A CN106728128A (en) 2016-12-10 2016-12-10 Prevent and treat the pharmaceutical composition of glaucoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611133180.6A CN106728128A (en) 2016-12-10 2016-12-10 Prevent and treat the pharmaceutical composition of glaucoma

Publications (1)

Publication Number Publication Date
CN106728128A true CN106728128A (en) 2017-05-31

Family

ID=58875017

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611133180.6A Withdrawn CN106728128A (en) 2016-12-10 2016-12-10 Prevent and treat the pharmaceutical composition of glaucoma

Country Status (1)

Country Link
CN (1) CN106728128A (en)

Similar Documents

Publication Publication Date Title
CN102631558A (en) Medicament for treating eye disease and preparation method of medicament
CN109512870B (en) Pharmaceutical composition, preparation method and application thereof
CN103211869A (en) Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof
CN106668348A (en) Pharmaceutical composition for treating diabetic retinopathy
CN104689107B (en) It is a kind of to be used to treat Chinese medicine composition of myopia and preparation method thereof
CN106728128A (en) Prevent and treat the pharmaceutical composition of glaucoma
CN104096153A (en) Pharmaceutical composition containing multiple plant active ingredients and preparation method and application thereof
CN106619816A (en) Pharmaceutical composition for treating optic atrophy
CN106109525A (en) The pharmaceutical composition for the treatment of chloasma
CN106822206A (en) It is a kind of to treat pharmaceutical composition of neurodermatitis and preparation method thereof
CN106668395A (en) Pharmaceutical composition for preventing and treating glaucoma
CN106620056A (en) Pharmaceutical composition for treating diabetic retinopathy
CN106668546A (en) Pharmaceutical composition for treating ceratitis
CN106727854A (en) A kind of pharmaceutical composition for treating synovitis
CN106668125A (en) Pharmaceutical composition for treating optic atrophy and preparation method of pharmaceutical composition
CN106511545A (en) Medicinal composition for treating vitreous opacity
CN106109927A (en) A kind of pharmaceutical composition treating chloasma and preparation method thereof
CN105998218A (en) Pharmaceutical composition for treating female chloasma
CN105477191A (en) Medicine composition for treating aged coronary heart disease
CN106619754A (en) Medicine compound for treating glaucoma
CN106581222A (en) Pharmaceutical composition for treating suspension of vitreous body
CN106728422A (en) It is a kind of to prevent and treat pharmaceutical composition of glaucoma and preparation method thereof
CN106540090A (en) Prevent and treat pharmaceutical composition of optic atrophy and preparation method thereof
CN106728512A (en) It is a kind of to prevent and treat pharmaceutical composition of osteoporosis and preparation method thereof
CN106511434A (en) Pharmaceutical composition treating keratitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20170531